IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells
- PMID: 10543935
- DOI: 10.1054/ghir.1999.0113
IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells
Abstract
IGF-responsive breast cancer cells activate insulin receptor substrate (IRS)-1 after IGF-I treatment. To determine if IRS-1 expression was sufficient to enable IGF-responsiveness, two IGF-I unresponsive breast cancer cell lines (MDA-MB-435A and MDA-MB-468) were transfected with IRS-1. While IGF-I caused tyrosine phosphorylation of IRS-1 in both transfected cell lines, increased MAP kinase activity was not seen. IGF-I treatment of 435A IRS-1 transfected cells resulted in minimal increased PI3 kinase activity associated with IRS-1, while IRS-2/PI3 kinase was greatly reduced. In MDA-MB-468 IRS-1 transfected cells, IGF-I caused increased IRS-1 associated PI3 kinase activity compared to parental cells, but at levels far below those observed in IGF-responsive MCF-7 cells. The transfected cells were also not responsive to IGF-I in monolayer growth. Thus, IRS-1 expression and activation alone are insufficient to mediate a proliferative response to IGF-I in breast cancer cells, and it is likely that maximal activation of downstream signaling pathways must also occur.
Copyright 1999 Harcourt Publishers Ltd.
Similar articles
-
Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines.Oncogene. 2001 Nov 1;20(50):7318-25. doi: 10.1038/sj.onc.1204920. Oncogene. 2001. PMID: 11704861
-
A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.Cancer Res. 2003 Feb 1;63(3):627-35. Cancer Res. 2003. PMID: 12566306
-
Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.Cancer Res. 2001 Sep 15;61(18):6747-54. Cancer Res. 2001. PMID: 11559546
-
Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.J Exp Clin Cancer Res. 2004 Sep;23(3):385-94. J Exp Clin Cancer Res. 2004. PMID: 15595626 Review.
-
Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects.Mol Pathol. 2001 Jun;54(3):149-54. doi: 10.1136/mp.54.3.149. Mol Pathol. 2001. PMID: 11376126 Free PMC article. Review.
Cited by
-
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.Neoplasia. 2004 Mar-Apr;6(2):179-85. doi: 10.1593/neo.03316. Neoplasia. 2004. PMID: 15140407 Free PMC article.
-
Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.Mol Cancer Res. 2008 Sep;6(9):1491-8. doi: 10.1158/1541-7786.MCR-07-2173. Mol Cancer Res. 2008. PMID: 18819936 Free PMC article.
-
Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.Neoplasia. 2011 Jun;13(6):504-15. doi: 10.1593/neo.101590. Neoplasia. 2011. PMID: 21677874 Free PMC article.
-
The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.Oncogene. 2019 May;38(21):4015-4027. doi: 10.1038/s41388-019-0694-9. Epub 2019 Jan 28. Oncogene. 2019. PMID: 30692633 Free PMC article.
-
Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling.Oncogene. 2007 Nov 1;26(50):7132-42. doi: 10.1038/sj.onc.1210520. Epub 2007 May 7. Oncogene. 2007. PMID: 17486056 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous